Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2.

Publication date: May 03, 2025

mRNA vaccines have demonstrated considerable efficacy and safety against SARS-CoV-2, limiting the pandemic burden worldwide. The emergence of new variants of concern and the decline in neutralizing activity observed several weeks post-vaccination reinforced the call for repeated mRNA vaccination. We and others have shown that vaccine efficacy does not exclusively rely on antibody neutralizing activites; Fc-effector functions play an important role as well. However, it is well known that long-term exposure and repeated antigen stimulation elicit the IgG4 subclass of antibodies, which are inefficient at mediating Fc-effector functions. In this regard, recent studies highlighted concerns about IgG4 induction by mRNA vaccines. Here, we explored the impact of repeated mRNA vaccination on IgG4 induction and its impact on Fc-effector functions. We observed anti-Spike IgG4 elicitation after three doses of mRNA vaccine; the antibody levels further increased with additional doses. Vaccine-elicited IgG4 preferentially bound the ancestral D614G Spike. We also observed that Breakthrough Infection (BTI) after several doses of vaccine strongly increased IgG1 levels but had no impact on IgG4 levels, thereby improving Fc-effector functions. Finally, we observed that elderly donors vaccinated with Moderna mRNA vaccines elicited higher IgG4 levels and presented lower Fc-effector functions than donors vaccinated with the Pfizer mRNA vaccine. Altogether, our results highlight the importance of monitoring the IgG subclasses elicited by vaccination.

Open Access PDF

Concepts Keywords
D614g ADCC
Elderly Adult
Moderna Aged
Pandemic Antibodies, Neutralizing
Vaccine Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
elderly donors
Fc-effector functions
Female
Humans
humoral responses
IgG4
Immunoglobulin Fc Fragments
Immunoglobulin Fc Fragments
Immunoglobulin G
Immunoglobulin G
Male
Middle Aged
mRNA Vaccines
mRNA Vaccines
neutralization
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccination
Vaccines, Synthetic
Vaccines, Synthetic

Semantics

Type Source Name
disease IDO role
disease MESH Breakthrough Infection
disease MESH COVID 19
disease MESH infection
disease IDO host
disease IDO assay
disease MESH viral infections
disease IDO blood
drug DRUGBANK Flunarizine
drug DRUGBANK Immune Globulin Human
disease MESH AIDS
disease IDO reagent
drug DRUGBANK Phosphate ion
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Proline
drug DRUGBANK Streptomycin
drug DRUGBANK Ciclosporin
drug DRUGBANK Tromethamine
drug DRUGBANK Magnesium sulfate
drug DRUGBANK ATP
drug DRUGBANK Potassium
pathway REACTOME Immune System
disease IDO production
pathway KEGG Viral replication
drug DRUGBANK Coenzyme M
disease MESH Emergencies
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Carboxyamidotriazole
disease IDO symptom
disease MESH Infectious Diseases
disease MESH Immune Tolerance
disease IDO protein
disease MESH comorbidity

Original Article

(Visited 1 times, 1 visits today)